Bain Capital acquires 60.84% of Classys for KRW 669.9bn
- Deal value
- $462m
- Stake
- 60.84%
- Implied 100%
- $759m
- Revenue
- $69m
- Op. income
- $36m
- Multiples
- EQV/EBIT 21.3xPSR 10.9x
Deal value ÷ stake (structure unconfirmed)
2021 연결 · DART-verified
2021 연결 · DART-verified
On implied equity value
DART 20220322000792
- Target
- Classys · Aesthetic medical devices
- Buyer
- Bain Capital · FI
- Seller
- CEO Jung Sung-jae and related parties
- Structure
- —
- Announced
- Jan 27, 2022
- Closed
- —
- Stage
- Closed
Target
Classys, founded in 2007 by dermatologist Jung Sung-jae, makes aesthetic medical devices for clinics, best known for the HIFU device Shurink, with the Classys (clinic), Cluederm (aesthetic) and Scedum (personal) brands and exports to about 60 countries. Listed on KOSDAQ in 2017.
Deal rationale
According to DailyMedi, Bain Capital reportedly decided to invest after confirming Classys's product competitiveness and global growth potential, and a Classys official said the partnership would be a major driver of growth. According to Seoul Economic Daily, founder Jung Sung-jae would stay involved for several years for management stability, keep 12.93%, and the company planned to hire a professional CEO to expand overseas. According to TheBell, Bain had approached Jung since autumn 2021 and funded the deal with KRW 354.9bn from its fund and KRW 315bn of acquisition financing, closing at the end of March 2022.
| Revenue | $69m |
| Operating income | $36m |
| EBITDA | — |
| Net income | — |
2021 연결 · DART-verified · 20220322000792
Press coverage
- 데일리메디 (2022-01-27): “거래 금액은 약 6700억원이다.”
- 서울경제 (2022-01-27): “총 금액은 6,700억 원으로”
- 더벨 (2022-12-29): “지분 60.84%를 6699억원에 매입하는 주식매매계약(SPA)을”
- 딜사이트 (2022-04-22): “지난해 연결재무제표 기준으로 클래시스의 매출(1006억원)”
This is a data entry summarising filings and press reports. Please check the original sources for the figures.